	US 11,738,044 B2
	Extended use zirconium silicate compositions and methods of use thereof
Donald Jeffrey Keyser, Southlake, TX (US); and Alvaro F. Guillem, Lantana, TX (US)
Assigned to ZS PHARMA, INC., Coppell, TX (US)
Filed by ZS Pharma, Inc., Coppell, TX (US)
Filed on May 17, 2019, as Appl. No. 16/415,550.
Application 16/415,550 is a division of application No. 15/421,132, filed on Jan. 31, 2017, granted, now 10,300,087.
Application 15/421,132 is a continuation of application No. 14/883,428, filed on Oct. 14, 2015, granted, now 9,592,253, issued on Mar. 14, 2017.
Prior Publication US 2019/0365800 A1, Dec. 5, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/24 (2019.01); C01B 39/02 (2006.01); A61K 9/16 (2006.01); B01J 39/02 (2006.01); B01J 39/14 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01)

CPC A61K 33/24 (2013.01) [A61K 9/16 (2013.01); B01J 39/02 (2013.01); B01J 39/14 (2013.01); C01B 39/02 (2013.01); A61K 9/0053 (2013.01); A61K 9/14 (2013.01)]

13 Claims

1. A method of treatment of hyperkalemia comprising administering over a period of more than 5 consecutive days to a patient in need thereof a cation exchange composition comprising a zirconium silicate of formula (I):

A_pM_xZr_1-xSi_nGe_yO_m (I)

where

A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof,

M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof,

“p” has a value from about 1 to about 20,

“x” has a value from 0 to less than 1,

“n” has a value from about 0 to about 12,

“y” has a value from 0 to about 12,

“m” has a value from about 3 to about 36 and 1≤n+y≤12,

wherein the composition exhibits a lead content below 0.6 ppm.